Experience of Treatment with Everolimus in Patients with Well-Differentiated Neuroendocrine Tumors (NET) of Various Localizations at the NN Blokhin NMRCO, Moscow, Russia


Introduction: Everolimus (EVE) (mTOR inhibitor) is an effective drug in the treatment of well-differentiated NETs of different localizations, however, prognostic factors for the correct choice of therapy are not well understood.

Aim(s): Evaluate the efficacy and toxicity of EVE in Russian patient population and identify factors of prognostic value.

Materials and methods: 90 pts (30 men, 60 women) with well-differentiated NETs (pNETs - 35 pts, gastrointestinal - 26, lungs -12, CUP - 14, uterus - 2, retroperitoneal space - 1 patient) were evaluated. Functional tumors - 48.9% (clinical manifestations - 6 pts, clinical manifestations + biochemical parameters - 38 pts). Only an increase in biochemical markers in 36.7% pts. G1 – 23,3%, G2-75,6%, G3- 1,1%. 61 pts- surgical treatment, 57 - chemotherapy, 24 –α-INF, 69 - SSA, 7 - sunitinib, 7 pts - did not receive treatment before. Factors analyzed: localization, metastasis zones, surgery, SSA, ECOG, carcinoid syndrome, chromogranin, serotonin. Univariate and multivariate analysis was carried out.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Markovich A, Kuznetsova A, Gorbunova V, Orel N, Emelianova G,

Keywords: neuroendocrine tumors, everolimus, uni- and multivariate analysis,

To read the full abstract, please log into your ENETS Member account.